Skip to content
value.today

Accelerate Diagnostics, Inc.

AXDXUnlisted company
$58 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$12 M
For year ending December-2024
Net income
$-50 M
-427.7% margin
SEC filing
Employees
275
2019
Wikidata

Accelerate Diagnostics, Inc. in brief

Accelerate Diagnostics, Inc. is an unlisted company in the Diagnostics and Research industry, based in Tucson, Arizona, USA. It was founded in 1987. In the year to December 2024 it had sales of $12 M and a net loss of $50 M. It employs about 275 people.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics is an Vitro Diagnostics company. The headquarters is in USA.

Accelerate Diagnostics, Inc. timeline

5 events, 1987–2022
  1. 1987
  2. 🏁
    · approximate
    Founded
  3. 1995
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2012
  6. 🔔
    · approximate
    Initial public offering on Nasdaq as AXDX
  7. ✎
    Renamed Accelerate Diagnostics, Inc
    Formerly Accelr8 Technology Corp.
  8. 2022
  9. 💰
    Record revenue of $13 million
    FY2022, the highest of the 7 years on record.

Events of Accelerate Diagnostics, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Accelerate Diagnostics, Inc.

Acquisitions and changes
Delisted: the exchange removed its shares from listing (Form 25-NSE) on 21 July 2025.

Market cap history

$0 M$254 M$508 M$762 M$1.0 B20202021202220232024

World rank over time

▼ down 16,322 places since 2020
2020-01-01: #7898#7,89820202021-01-01: #11868#11,86820212022-01-07: #16246#16,24620222022-12-25: #24560#24,56020222023-07-30: #21757#21,75720232024-01-05: #24220#24,2202024

Rank in USA: #1,984 (Jan 2020) · #2,865 (Jan 2021) · #3,408 (Jan 2022) · #4,692 (Dec 2022) · #4,235 (Jul 2023) · #3,996 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-427.7%
Operating margin
-301.8%
Return on equity
—
Liabilities / assets
296.2%
Net debt
$-40M
Revenue growth
-3.0%
R&D / revenue
142.6%
Revenue per employee
$43 K
Profit per employee
$-182 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue $4M, net income $-64M$4MFY17Fiscal year ending Dec 2018: revenue $6M, net income $-88M$6MFY18Fiscal year ending Dec 2019: revenue $9M, net income $-84M$9MFY19Fiscal year ending Dec 2020: revenue $11M, net income $-78M$11MFY20Fiscal year ending Dec 2021: revenue $12M, net income $-78M$12MFY21Fiscal year ending Dec 2022: revenue $13M, net income $-62M$13MFY22Fiscal year ending Dec 2023: revenue $12M, net income $-62M$12MFY23Fiscal year ending Dec 2024: revenue $12M, net income $-50M$12MFY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024$12M-3.0%$-35M$-50M-427.7%
Dec 2023$12M-5.4%$-54M$-62M-510.9%
Dec 2022$13M+8.2%$-63M$-62M-490.1%
Dec 2021$12M+5.6%$-72M$-78M-659.6%
Dec 2020$11M+20.0%$-64M$-78M-700.8%
Dec 2019$9M+64.0%$-73M$-84M-906.5%
Dec 2018$6M+35.6%$-80M$-88M-1557.8%
Dec 2017$4M—$-64M$-64M-1531.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$-24M$1M$-25M$-2.15—
Dec 2023$-40M$1M$-41M$-4.94—
Dec 2022$-49M$1M$-49M$-7.61—
Dec 2021$-47M$1M$-48M$-12.59—
Dec 2020$-50M$1M$-52M$-1.40—
Dec 2019$-65M$0M$-65M$-1.55—
Dec 2018$-68M$1M$-69M$-1.62—
Dec 2017$-56M$3M$-59M$-1.18—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$12M
Net income, trailing 12 months
$-50M
RevenueNet income
Three months to Mar 2023: revenue $3M, net income $-17M$3MMar ’23Three months to Jun 2023: revenue $3M, net income $-33M$3MJun ’23Three months to Sep 2023: revenue $3M, net income $1M$3MSep ’23Three months to Dec 2023 (from the annual report): revenue $3M, net income $-13M$3MDec ’23Three months to Mar 2024: revenue $3M, net income $-14M$3MMar ’24Three months to Jun 2024: revenue $3M, net income $-12M$3MJun ’24Three months to Sep 2024: revenue $3M, net income $-15M$3MSep ’24Three months to Dec 2024 (from the annual report): revenue $3M, net income $-10M$3MDec ’24

Latest quarter to Dec 2024: revenue $3M (-7.3% on a year earlier), net income $-10M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Dec 2024.

SEC filings

Official filings of Accelerate Diagnostics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$12 M
Operating income
$-35 M
Net income
$-50 M

For year ending December-2024 · source: SEC filing

Balance sheet

Total assets
$29 M
Total liabilities
$85 M
Total equity
$-56 M

As of December-2024

Insider trading at Accelerate Diagnostics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
21
since
$314 K-$314 K$0Nov 2023: bought $0 (0 trades), sold $5 K (2 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $4 K (2 trades)Jan 2024: bought $0 (4 trades), sold $0 (0 trades)Jan 24Feb 2024: bought $0 (0 trades), sold $978 (2 trades)Apr 2024: bought $0 (0 trades), sold $82 K (6 trades)AprMay 2024: bought $0 (0 trades), sold $318 (2 trades)Dec 2024: bought $314 K (1 trades), sold $314 K (1 trades)DecFeb 2025: bought $0 (0 trades), sold $1 K (2 trades)Apr 2025: bought $0 (0 trades), sold $22 K (3 trades)Apr
Bought (open market)Sold (open market)Hover a month for the totals
Accelerate Diagnostics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Larry Michael MertzChief Technology OfficerOption exercise+4,298——86,326Form 4
filed Jack PhillipsChief Executive Officer, DirectorOption exercise+53,283——216,717Form 4
filed Larry Michael MertzChief Technology OfficerSell-1,523$0.650$99084,803Form 4
filed Jack PhillipsChief Executive Officer, DirectorSell-25,343$0.650$16 K191,374Form 4
filed David PatienceChief Financial OfficerOption exercise+20,000——71,384Form 4
filed David PatienceChief Financial OfficerSell-6,816$0.710$5 K64,568Form 4
filed David PatienceChief Financial OfficerOption exercise+1,500——51,919Form 4
filed David PatienceChief Financial OfficerSell-535$1.090$58351,384Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Accelerate Diagnostics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2025-04-30
297,377
1.2% of shares · 14.17 days to cover
Buybacks, Q4 2019
$0M
Q4 2019
Shares sold short, last 12 reportsAll stocks →

Stock splits: 1-for-10 reverse split

Bankruptcy filing: (8-K); (8-K)

Accelerate Diagnostics, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2019Q4 2019$0M
Q3 2019Q3 2019$0M
Q2 2019Q2 2019$0M
Q1 2019Q1 2019$0M
Q4 2018Q4 2018$0M
Q3 2018Q3 2018$0M
Q2 2018Q2 2018$0M
Q1 2018Q1 2018$45.1M
Q4 2017Q4 2018$0M
Q3 2017Q3 2018$0M
Q2 2017Q2 2018$0M
Q1 2017Q1 2018$0M

Fails to deliver

  • : 1.2 M shares at $0.03
  • : 19,615 shares at $0.13
  • : 22,147 shares at $0.15
  • : 115 shares at $0.49
  • : 189 shares at $0.52

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Accelerate Diagnostics, Inc. scorecard#

Passes 2 of the 13 checks that could be worked out: strongest in profitability (1 of 4), weakest in growth (1 of 6). Fiscal year 2024.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-3.0%Revenue down 3.0% in fiscal 2024.
    • ✗Revenue up more than 5% a year over three years-0.2%-0.2% a year over the three years to fiscal 2024.
    • ✗Faster growth over three years than its peers' median-0.2%-0.2% a year against Diagnostics and Research's median of 3.6% (64 companies).
    • ✗Earnings per share grew in the newest year-2.15 vs -4.94Diluted EPS -2.15 in fiscal 2024 against -4.94 the year before (report's currency).
    • ✓Net income higher than five years earlier-$50 M-$50 M in fiscal 2024 against -$84 M in 2019.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2024.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$50 MNet income -$50 M in fiscal 2024.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2024.
    • ✗Operating margin above its peers' median-301.8%-301.8% against Diagnostics and Research's median of -2.4% (66 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-301.8%-301.8% in fiscal 2024 against -607.5% in 2021.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.7×Current ratio 0.71 at the end of fiscal 2024.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year86.8%Diluted shares up 86.8% in fiscal 2024.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2024#

Worked out from Accelerate Diagnostics, Inc.'s statements, beside the median of Diagnostics and Research.

Accelerate Diagnostics, Inc.: main financial ratios in 2024
Ratio2024Median of peers
Operating margin-301.8%-2.4%
Net margin-427.7%-3.6%
Revenue growth, 3 years a year-0.2%3.6%
Revenue growth-3.0%6.6%
Free cash flow margin-211.1%4.7%

4of 8on the Piotroski tests of financial strength

  • Revenue fell 3.0% against the year before.
  • Net loss of $50 million, the 14th loss-making year in a row.
  • Free cash flow was negative: -$25 million.
  • The share count rose 86.8% in the year.

Accelerate Diagnostics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Accelerate Diagnostics, Inc.: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015
Income statement
Revenue12121312119.35.74.20.20.1
Cost of revenue9.09.59.4126.74.93.21.000
Gross profit2.72.63.3−0.44.54.42.53.20.20.1
Research and development172527222125282230r27r
Selling, general and administrative213139494752554537—
General and administrative———————4537r19r
Total costs and expenses38576671687783676746
Operating income−35−54−63−72−64−73−80−64−67−46
Interest and finance income0.71.10.60.10.92.82.80.90.50.1
Interest expense and finance costs——2.3161614r10———
Net interest income————−16−14−1000−0.0
Other non-operating income (expense)−15−6.70.2−6.1−15−12−7.70.60.4—
Income before tax−50−61−63−78−78−84−88−64−66−45
Income tax−0.10.9−0.10.00.0−0.10.20.50.30
Net income including minority interests—————————−45
Net income attributable to shareholders−50−62−62−78−78−84−88−64−66−45
Earnings per share, basic-2.15-4.94-7.61r-12.59r-1.40-1.55-1.62-1.18-1.29-1.01
Earnings per share, diluted-2.15-4.94-7.61r-12.59r-1.40-1.55-1.62-1.18-1.29-1.01
Shares, weighted average (basic)23128.2r6.2r565554545145
Shares, weighted average (diluted)23128.2r6.2r5655————
Balance sheet
Cash and cash equivalents151235403661662919121
Short-term investments1.21.111———————
Receivables2.02.62.4r2.31.63.21.91.90.00.1
Inventory2.93.35.25.19.28.17.78.10—
Other current assets0.81.52.01.61.81.20.60.50.20.0
Current assets222456738212217812078134
Property, plant and equipment2.62.43.55.46.17.97.34.94.35.0
Right-of-use (leased) assets2.91.21.92.53.23.9————
Other intangible assets——————0.10.10.10.2
Total assets293165839313418512683139
Accounts payable4.84.84.52.01.32.41.32.11.02.6
Debt due within a year—0.7560.10.60————
Current liabilities3112676.97.08.27.86.84.05.3
Long-term debt———04.70———0
Lease liabilities (non-current)2.60.61.52.43.13.6————
Total liabilities8551871181561421286.85.06.3
Retained earnings−719−669−607−571−493−415−330−242−177−111
Shareholders' equity−56−20−22−35−63r−7.45711978133
Total liabilities and equity293165839313418512683139
Shares outstanding25159.7r68585554r565251r
Cash-flow statement
Depreciation and amortization1.41.31.72.02.42.32.52.22.3r1.8r
Share-based compensation4.45.41122161314148.88.4
Cash from operating activities−24−40−49−47−50−65−68−56−53−35
Capital expenditure−0.5−1.0−0.6−0.6−1.4−0.3−1.0−3.0−2.4−3.7
Cash from investing activities−0.58.7128.31453−20−26−50−2.7
Debt issued150005.60————
Debt repaid−0.70−0.1−0.4−0.400———
Shares issued——33430.41.5————
Shares bought back————00−4500—
Cash from financing activities279.03243126.8126901.8105
Exchange-rate effect on cash0.6−0.3−0.3−0.1−0.1−0.1−0.10.3−0.10
Change in cash3.0−23−5.04.1−25−5.2389.3−10167
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Accelerate Diagnostics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Bankruptcy or receivershipFiling
  • Delisting noticeFiling
  • Bankruptcy or receivershipDebt called earlyFiling
  • Delisting noticeFiling
  • Auditor changedFiling
  • Delisting noticeFiling

And 1 more in the list below.

Bankruptcy or receivership 2 · Delisting notice 4 · Auditor changed 1 · Debt called early 1 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 6 · New debt 2 · Unregistered share sale 2 · Shareholder vote 1 · Results announced 8

Accelerate Diagnostics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Bankruptcy or receivershipAcquisition or sale completedMaterial agreement8-K
Material agreement8-K
Directors and officers8-K
Delisting notice8-K
Bankruptcy or receivershipDebt called earlyMaterial agreementNew debt8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreementNew debt8-K
Auditor changed8-K
Directors and officers8-K
Unregistered share sale8-K
Directors and officersShareholder vote8-K
Results announced8-K/A
Results announced8-K
Delisting notice8-K
Results announced8-K
Delisting notice8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 18, 2025

Acquisitions and funding#

6 private funding rounds before listing

Private share sales · funding history

Private share sales of Accelerate Diagnostics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2022$4 MNo. 6$2 to $10 million3equitySEC
Sep 2021$30 MNo. 5$10 to $50 million3equitySEC
Dec 2020$2 MNo. 4Under $2 million5equitySEC
May 2014$20 MNo. 3$10 to $50 million4equitySEC
Aug 2013$3 MNo. 2$2 to $10 million1equitySEC
Jun 2012$14 MNo. 1$10 to $50 million1equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Accelerate Diagnostics, Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $65 K a year.

Certified, FY2025
1
#1,949 among companies on value.today
Worker positions
1
Median wage offered
$65 K
a year, full-time
Applications filed
1
Accelerate Diagnostics, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Associate Data ScientistStatisticians1$65 K

Where: Tucson, AZ 1

Accelerate Diagnostics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511$65 K1
FY202211$65 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Accelerate Diagnostics, Inc.

Product recalls by Accelerate Diagnostics, Inc.#

3 recalls since 2015, 376 units in the notices that give a number. Medical devices (FDA): 3.

Accelerate Diagnostics, Inc.: product recalls
DateWhat and whyUnitsNotice
Accelerate PhenoTest BC kit REF 10101018 (and 1 more products)Due improperly formulated and released bulk lot of fluorescence in situ hybridization (FISH) probes resulting in false positive identification results for Staphylococcus aureus and Streptococcus spp.Medical devicesClass II200Z-0345-2023
Accelerate PhenoTest BC kit, Ref #10101018. The firm name on the label is Accelerate Diagnostics, Tucson, AZ. A multiplexed in-vitro diagnostic test intended for use with the Accelerate Pheno system.The kits may produce an elevated rate of false positive calls for the Staphylococcus aureus identification probe (SAU).Medical devicesClass II95Z-1529-2018
Accelerate Pheno system, with Accelerate Pheno System Software 1.2.1 - 1.3.1, PSW000012B Product Usage: The Accelerate Pheno system is intended to measure signal intensity of fluorescent probes bound to nucleic acid in target and non-target organisms and to take time-lapse dark-field images of immobilized growing bacterial cell…Rare isolates of Enterobacteriaceae may generate a susceptible meropenem Minimum Inhibitory Concentration (MIC) using the affected device and a resistant result by broth microdilution. In order to mitigate any risk associated with these rare isolates, the firm has implemented an Expert Rule that suppresses the meropenem result for isolates that display a profile consistent with those that generated a false-susceptible result. The firm has responded to this risk by implementing a set of suppression rules, in a software update, to prevent incorrect results.Medical devicesClass II81Z-1065-2019

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

How Accelerate Diagnostics, Inc. compares in Diagnostics and Research

  • Revenue$12 M · higher than 16% of 123
  • Net margin-427.7% · higher than 3% of 112
  • Revenue growth-3.0% · higher than 23% of 89

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
Accelerate Diagnostics, Inc.🇺🇸$58 M—-427.7%-3.0%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Employees:
2019
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Accelerate Diagnostics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Accelerate Diagnostics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Accelerate Diagnostics, Inc.? Suggest a correction